Medical cannabis may give modest benefits for chronic pain

A minority of people living with chronic pain who try medical cannabis may experience relief and the risk of side effects is typically small, says an international study led by McMaster scientists.

September 15, 2021

Expert Featured In This Story

Justin Busse
Justin Busse

Assistant Clinical Professor (Adjunct)

See Profile

A minority of people living with chronic pain who try medical cannabis may experience important relief and the risk of side effects is typically small, says an international study led by McMaster University scientists.

Data from 32 randomized controlled trials showed that use of non-inhaled medical cannabis versus placebo resulted in small to very small improvements in pain relief, physical functioning, and sleep quality. There was no difference in emotional, social or role functioning.

Medical cannabis also resulted in, typically, a small to very small increase of transient side effects, such as dizziness, drowsiness, impaired attention and nausea.

“There are a lot of harms that people talk about with cannabis, such as early onset psychosis affecting teens and adults, or becoming addicted, but this evidence has been based on recreational cannabis use,” said senior author Jason Busse, associate director of McMaster’s Michael G. DeGroote Centre for Medicinal Cannabis Research and associate professor of anesthesia.

He added that given the close balance between benefits and harms, an associated guideline made a weak recommendation to consider a trial of medical cannabis for people living with chronic pain, in whom standard care was not sufficient.

“Future research should compare long-term and serious harms of medical cannabis with other management options for chronic pain, including opioids,” said Busse.

Both studies were published in The British Medical Journal.

In a separate study published in BMJ Open, researchers discovered that patient attitudes towards medical cannabis were highly variable, influenced by positive factors such as support from family and friends, but also by societal stigma surrounding its use.

“The variability of patients’ attitudes and preferences reflects the need for shared decision-making with clinicians when considering medical cannabis for chronic pain,” said Busse.

Funding was provided by the Canadian Institutes of Health Research and the Michael G. DeGroote Centre for Medicinal Cannabis Research.

Marek Smieja smiles while standing outside on a bright day.

McMaster scientist Marek Smieja receives prestigious national award for infectious disease research 

The John G. FitzGerald Award recognizes Smieja for advancing the diagnosis and epidemiology of respiratory and gastrointestinal infections, including those caused by SARS-CoV-2, influenza, rhinovirus, and C. difficile.
Toronto skyline enveloped in yellowish smog.

Everyday air pollution linked to poorer brain function, study finds

New research suggests that fine particles from traffic, industry and wildfire smoke are linked to worse cognitive function.
Smiling Sheila Singh wearing a McMaster lab coat, looking over lab equipment.

New McMaster-made drug candidate shows promise as a brain cancer treatment 

The drug candidate can eliminate deadly and aggressive glioblastoma tumours, which typically resist standard treatments and often recur rapidly.